M12.F M1 Kliniken AG
- Market cap
- EUR 371M
- P/E
- 19.6x
- P/B
- 2.87x
- ROE
- 18.5%
- Dividend yield
- 2.51%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is M12.F undervalued?
Graham numberM12.F trades 58.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
M1 Kliniken AG fundamental analysis
No fundamental analysis for M1 Kliniken AG yet.
M1 Kliniken AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About M1 Kliniken AG
M1 Kliniken AG, together with its subsidiaries, provides aesthetic medicine and plastic surgery services in Germany, Austria, the Netherlands, Switzerland, Croatia, Hungary, Bulgaria, and Romania. It operates through Beauty and Trade segments. The Beauty segment provides aesthetic surgery services, such as breast augmentation, eyelid lifts, and liposuction; and other aesthetic medical treatment services, including injections with hyaluronic acid and botulinum toxin. This seg…
Full company profileM1 Kliniken AG financial statements
M1 Kliniken AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 36.0M | 47.2M | 65.2M | 77.2M | 160M | 315M | 285M | 316M | 339M | 364M |
| Gross Profit | 8.02M | 18.5M | 22.9M | 31.6M | 36.8M | 55.3M | 52.8M | 50.2M | 63.6M | 82.6M |
| Operating Income | -1.06M | 5.71M | 6.46M | 7.81M | 9.18M | 12.1M | 8.94M | 14.6M | 26.1M | 36.7M |
| EBITDA | - | 7.83M | 8.81M | 16.5M | 14.0M | 21.0M | 17.1M | 23.1M | 33.4M | 40.5M |
| Net Income | 5.01M | 5.78M | 6.61M | 9.73M | 6.82M | 8.91M | 4.32M | 10.3M | 16.0M | 22.1M |
| EPS | - | 0.35 | 0.38 | 0.56 | 0.37 | 0.48 | 0.24 | 0.54 | 0.84 | 1.18 |
| Balance Sheet | ||||||||||
| Total Assets | 32.2M | 50.6M | 69.6M | 92.8M | 189M | 198M | 197M | 213M | 188M | 189M |
| Total Liabilities | 1.93M | 3.29M | 5.81M | 24.6M | 73.4M | 58.2M | 54.0M | 69.7M | 53.7M | 39.3M |
| Shareholders' Equity | 30.3M | 47.3M | 63.7M | 68.2M | 85.8M | 95.0M | 93.6M | 113M | 106M | 120M |
| Cash & Short-term Investments | 5.81M | 14.7M | 25.4M | 9.10M | 22.0M | 37.9M | 35.1M | 22.4M | 21.4M | 37.8M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 7.94M | 2.09M | 2.86M | -5.37M | 9.54M | 15.7M | 20.8M | 7.81M | 30.5M | 37.9M |
| Capital Expenditure | 842K | 3.29M | 2.10M | 1.06M | 907K | 1.03M | 1.16M | 1.01M | 768K | 110K |
| Free Cash Flow | - | -1.34M | 533K | -6.72M | 8.09M | 14.3M | 19.0M | 6.80M | 29.8M | 37.8M |
| Ratios | ||||||||||
| ROE | 16.5% | 12.2% | 10.4% | 14.3% | 8.0% | 9.4% | 4.6% | 9.1% | 15.1% | 18.5% |
| ROA | 15.6% | 11.4% | 9.5% | 10.5% | 3.6% | 4.5% | 2.2% | 4.8% | 8.5% | 11.7% |
| Net Profit Margin | 13.9% | 12.2% | 10.1% | 12.6% | 4.3% | 2.8% | 1.5% | 3.2% | 4.7% | 6.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
M1 Kliniken AG dividends
- Dividend yield
- 2.51%
- Forward dividend
- 1.20 EUR
- Payout ratio
- 42.1%
- Ex-dividend date
- Jul 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 9.31M | 0.50 | 42.1% |
| 2024 | EUR 9.31M | 0.49 | 58.1% |
| 2023 | EUR 1.98M | 0.10 | 19.3% |
| 2022 | EUR 1.82M | 0.10 | 42.2% |
| 2021 | EUR 1.66M | 0.09 | 18.6% |
| 2020 | EUR 129K | 0.01 | 1.9% |
| 2019 | EUR 5.25M | 0.30 | 54.0% |
| 2018 | EUR 4.95M | 0.28 | 74.9% |
| 2017 | EUR 4.50M | 0.27 | 77.9% |
| 2016 | EUR 4.50M | - | 89.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns M1 Kliniken AG
- Insiders 0.00%
- Institutions 1.47%
- Public & others 98.53%
- Shares outstanding 18.6M
- Free float 18.6M
M1 Kliniken AG company profile
- Company name
- M1 Kliniken AG
- Ticker
- M12.F
- ISIN
- DE000A0STSQ8
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 280
- Fiscal year end
- December
- Address
- Grünauer Straße 5, Berlin, Germany, 12557
- Phone
- 49 30 347 47 44 14
- Website
- m1-kliniken.de
About M1 Kliniken AG
M1 Kliniken AG, together with its subsidiaries, provides aesthetic medicine and plastic surgery services in Germany, Austria, the Netherlands, Switzerland, Croatia, Hungary, Bulgaria, and Romania. It operates through Beauty and Trade segments. The Beauty segment provides aesthetic surgery services, such as breast augmentation, eyelid lifts, and liposuction; and other aesthetic medical treatment services, including injections with hyaluronic acid and botulinum toxin. This segment also manages a private clinic for plastic and aesthetic surgery; and medical specialist centers for aesthetic and plastic medicine under the Schlossklinik and M1 Med Beauty names. The Trade segment sells pharmaceuticals and medical products for various therapeutic areas of oncology, HIV/AIDS, neurology, rheumatology, other chronic diseases, and aesthetic medicine. The company was incorporated in 2007 and is based in Berlin, Germany. M1 Kliniken AG is a subsidiary of MPH Health Care AG.
M1 Kliniken AG management
2- Mr. Attila StraussMember of Management Board & CEO
- Ms. Katharina ZimmnauCFO & Member of Executive Board